BioSpace News Archive

Business

Kite Taps Industry Vet to Lead Cell Therapy Research

Kite Pharma has tapped immunotherapy expert Francesco Marincola, a former National Institutes of Health investigator, to helm the company’s cell therapy research.

January 19, 2021
·
2 min read
·
Alex Keown
Drug Development

Nanoparticle Vaccine: The Next Generation of Vaccine Technology

The nanoparticle vaccine development is going to be a great leap in vaccine technology. Here is everything you need to know about the upcoming technology.

January 19, 2021
·
4 min read
·
Mark Terry
Deals

Thermo Fisher Buys Mesa Biotech for a Total Deal of $550 Million

Thermo Fisher Scientific, based in Waltham, Massachusetts, is acquiring Mesa Biotech for about $450 million in cash. There is also an additional $100 million in cash after certain milestones are hit.

January 19, 2021
·
2 min read
·
Mark Terry
Business

Lilly’s Loxo Oncology Stakes Up to $1 Billion in Merus’ T-Cell Antibody Cancer Candidates

Indianapolis-based Eli Lilly is betting big on clinical-stage oncology company Merus, agreeing to pay up to $1.6 billion to the Netherlands-based biotech for a research and development collaboration focused on up to three early experimental cancer drugs.

January 19, 2021
·
3 min read
·
Brandon May
Drug Development

Verrica Presents Promising Phase III Results for Molluscum & Genital Warts Treatment

VP-102, which has the potential to be the first product approved by the FDA for the treatment of molluscum contagiosum, contains a GMP-controlled formulation of cantharidin (0.7% w/v), which is delivered via a single-use applicator that allows for precise topic dosing and targeted administration.

January 19, 2021
·
2 min read
·
Heather McKenzie
Drug Development

Race to Vaccinate Increases as COVID-19 Virus Mutates Again

New variants of COVID-19 are popping up all across the globe, including here in the United States.

January 19, 2021
·
3 min read
·
Alex Keown
Drug Development

2021 Biopharma Update on the Novel Coronavirus: January 19

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.

January 19, 2021
·
6 min read
·
BioSpace Editorial Staff
FDA

FDA Grants Rare Pediatric Disease, Orphan Drug Designation to Taysha’s Rare Epilepsy Candidate

The U.S. FDA has granted rare pediatric disease and orphan drug designations for Taysha Gene Therapies’ AAV9-based gene treatment candidate currently in development for epilepsy caused by SLC13A5 deficiency.

January 19, 2021
·
3 min read
·
Brandon May
$80 Million-Plus Venture Rounds for Gene Editing, Fusion Protein Companies

Sizable venture rounds from cardiac gene-editing company Verve Therapeutics and the retooled fusion protein maker Vera Therapeutics will push their lead therapies into and through the clinic over the next two years.

January 19, 2021
·
2 min read
·
Mark Zipkin
Using Cutting Edge Tech, Georgetown Team Proves Pancreatic Cancer Target

Pancreatic cancer is one of the deadliest forms of cancer. The five-year survival rate is a paltry 5-10%. The tumors are basically invisible to the immune system and rarely respond to chemotherapy or immunotherapy.

January 19, 2021
·
4 min read
·
Kate Goodwin